Sign in
Taking people in AustriaPhase 4

Measuring antibiotic levels in the lungs of people with COPD or cystic fibrosis

Compares ways of measuring lung antibiotic levels in COPD and cystic fibrosis.

Key facts

Who runs it
Medical University Of Vienna
Where
Vienna, AustriaSee the site
Registry title
Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo microdialysis and tissue biopsy. An exploratory pharmacokinetic study.
Status
Recruiting
Phase
Phase 4
People taking part
18 people, planned
Started
11 Dec 2024
Planned end
31 Dec 2025
Type of study
Interventional
Record updated
11 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with COPD or cystic fibrosis who are planned to have a lung transplant on both sides. It compares three ways to measure antibiotic levels in the lung.

Age
Older than 18 and younger than 90 years.
Sex
Men and women can join.
Disease stage
COPD or cystic fibrosis, with a planned lung transplant on both sides (bilateral).
Earlier treatment
People who already had a lung transplant cannot join.

Main reasons for not taking part

  • Cannot give informed consent
  • Known allergy to the study drugs
  • Prior lung transplantation
  • Kidney failure before surgery, or chronic severe kidney problems including haemodialysis
  • Chronic severe liver disease or ECLS bridging

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Written informed consent
  • Planned bilateral lung transplantation
  • Diagnosis of COPD or CF
  • Age: > 18 and < 90 years

Who cannot take part

  • Prior lung transplantation
  • Known allergy to study drugs
  • Preoperative renal failure
  • Chronic severe renal insufficiency including haemodialysis
  • Chronic severe liver disease
  • Inability to give informed consent
  • ECLS bridging

Where in Austria

  • Medical University of ViennaVienna, AustriaTaking people

About the trial

What the trial wants to find out

The primary objective is the head-to-head comparison of three methods for measuring pulmonary antibiotic pharmacokinetics. Epithelial lining fluid concentrations at 75', tissue biopsy concentrations at 75' and in-vivo microdialysis concentrations during the 60-90' interval will be compared.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo microdialysis and tissue biopsy. An exploratory pharmacokinetic study.
Plain-language title
Measuring antibiotic levels in the lungs of people with COPD or cystic fibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
11 December 2024